Bordetella pertussis strains with increased toxin production associated with pertussis resurgence. by Mooi, F.R. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/80795
 
 
 
Please be advised that this information was generated on 2017-12-06 and may be subject to
change.
Before childhood vaccination was introduced in the 
1940s, pertussis was a major cause of infant death world-
wide. Widespread vaccination of children succeeded in 
reducing illness and death. In the 1990s, a resurgence of 
pertussis was observed in a number of countries with high-
ly vaccinated populations, and pertussis has become the 
most prevalent vaccine-preventable disease in industrial-
ized	countries.	We	present	evidence	that	in	the	Netherlands	
the dramatic increase in pertussis is temporally associated 
with the emergence of Bordetella pertussis strains carrying 
a novel allele for the pertussis toxin promoter, which confers 
increased pertussis toxin (Ptx) production. Epidemiologic 
data suggest that these strains are more virulent in humans. 
We discuss changes in the ecology of B. pertussis that may 
have driven this adaptation. Our results underline the impor-
tance of Ptx in transmission, suggest that vaccination may 
select for increased virulence, and indicate ways to control 
pertussis more effectively.
Bordetella pertussis causes whooping cough or pertus-sis, a respiratory disease that is most severe in infants. 
Before childhood vaccination was introduced in the 1940s, 
pertussis was a major cause of infant deaths worldwide. 
Widespread vaccination of children reduced the incidence 
of illness and deaths caused by pertussis (1). However, 
globally pertussis remains 1 of the top 10 causes of death in 
children (2). Further, in the 1990s a resurgence of pertussis 
was observed in several countries with highly vaccinated 
populations (3,4), and pertussis has become the most preva-
lent vaccine-preventable disease in industrialized countries. 
In the Netherlands, the estimated incidence of infection 
was 6.6% per year for the 3–79-year age group from 1995 
through 1996 (5). Similar percentages have been found in 
the United States (6). One of the hallmarks of the pertussis 
resurgence is a shift in disease prevalence toward older per-
sons who have waning vaccine-induced immunity (7). 
The reemergence of pertussis has been attributed to 
various factors, including increased awareness, improved 
diagnostics, decreased vaccination coverage, suboptimal 
vaccines, waning vaccine-induced immunity, and pathogen 
adaptation. The relative contribution of these factors may 
differ between countries and is the subject of ongoing de-
bate. Pathogen adaptation is supported by several observa-
tions. We and others have shown that antigenic divergence 
has occurred between vaccine strains and clinical isolates 
with respect to surface proteins, which confer protective 
immunity: pertussis toxin (Ptx), pertactin (Prn), and fim-
briae (8,9). Strain variation was shown to affect vaccine ef-
ficacy in a mouse model (10–13). Because adaptation may 
involve the structure of virulence factors (by antigenic vari-
ation) and their regulation, we extended our studies on the 
evolution of B. pertussis by investigating polymorphism in 
the promoter of Ptx (ptxP), a major virulence factor and 
component of all pertussis vaccines (1). We provide evi-
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Toxin Production and Pertussis Resurgence
dence that expansion of strains with increased Ptx produc-
tion has contributed to the resurgence of pertussis in the 
Netherlands.
Methods
Pertussis Notifications
Pertussis became a notifiable disease in the Nether-
lands in 1976. Notifications are submitted online by local 
health authorities. Other notifiable diseases are also moni-
tored through this system, which falls under the responsi-
bility of the Dutch National Institute of Health and Envi-
ronment (3).
Bacterial Strains 
B. pertussis strains examined were obtained from 1935 
through 2004. A total of 1,566 isolates, 879 from the Neth-
erlands and 687 from other countries, were analyzed for 
polymorphism in ptxP (online Technical Appendix, avail-
able from www.cdc.gov/EID/content/15/8/1206-Techapp.
xls). Eight strains isolated from patients in the Netherlands 
from 1999 through 2001 were selected to study Ptx and 
Prn production: B1834 (ptxP1), B1868 (ptxP1), B1878 
(ptxP1), B1920 (ptxP1), B1836 (ptxP3), B1865 (ptxP3), 
B1917 (ptxP3), and B2030 (ptxP3) (Table 1).
Sequencing 
The primers 5′-AATCGTCCTGCTCAACCGCC-3′ 
and 5′-GGTATACGGTGGCGGGAGGA-3′ were used for 
amplification and sequencing of ptxP and correspond, re-
spectively, to bases 60–79 and 633–614 of the ptx sequence 
with GenBank accession no. M14378. The ptx gene clus-
ter from the strains B1834 (ptxP1), B1920 (ptxP1), B1917 
(ptxP3), and B1831 (ptxP3) was sequenced completely. 
The sequences of the ptx gene clusters from strains B1834, 
B1920, B1917, and B1831 can be found under the following 
accession numbers, respectively: FN252334, FN252335, 
FN252336, and FN252333. The ptxP1-ptxP11 sequences 
have been assigned accession nos. FN252323, FN252322, 
FN252324, FN252325, FN252326, FN252327, FN252328, 
FN252329, FN252330, FN252331, and FN252332.
Pertussis Toxin and Pertactin Production 
B. pertussis strains were grown on Bordet-Gengou 
agar plates supplemented with 15% sheep blood and in-
cubated for 3 days at 35°C. Cells were harvested and sus-
pended in 2 mL Verwey medium (14) per plate. Cells from 
1 mL were collected by centrifugation and resuspended in 
Verwey medium to a concentration of 5 × 106 bacteria/mL. 
Subsequently, 100 µL of this suspension (5 × 105 CFU) was 
plated on Bordet-Gengou agar plates. After an incubation 
of 48 to 60 hours at 35°C, cells were harvested in 2.5 mL 
Verwey medium. The cell suspension was heat-inactivat-
ed for 30 min at 56°C and stored at 4°C. An ELISA was 
used to quantify Ptx and Prn. For Ptx, Maxisorp 96-well 
plates (Nunc International, Rochester, NY, USA) were 
coated with 100 µL of 0.04 mg/mL fetuin (Sigma-Aldrich, 
St. Louis, MO, USA) in 0.04 M carbonate buffer, pH 9.6, 
overnight at 4°C. For Prn, polystyrene 96-well plates (Im-
munolon II; Dynatech, Chantilly, VA, USA) were coated 
with 100 µL of a 2,000-fold dilution of polyclonal rabbit 
anti-Prn immunoglobulin (Ig)G (15) in 0.04 M carbonate 
buffer, pH 9.6, overnight at 20°C. Plates were blocked by 
incubation with 130 µL 1% bovine serum albumin (Sigma-
Aldrich) in phosphate-buffered saline (PBS) for 1 hour 
at 37°C, after which plates were washed twice with PBS 
supplemented with 0.05% Tween. A 3-fold serial dilution 
of the heat-inactivated cell suspensions was made in 100 
µL PBS supplemented with 0.1% Tween (PBST); 1 µg/
mL of Prn and Ptx were used as reference. The suspensions 
were incubated for 1 hour at 37°C followed by 2 wash-
ings. The Prn monoclonal antibody (MAb) (PeM85) that 
was used binds to the linear epitope GGFGPGGFGP pres-
ent in the repeat region 1 of all known Prn variants, except 
Prn13 (15). The Ptx MAb (3F10) binds to a conformational 
epitope in the PtxA subunit (16). All strains selected for 
the ELISA experiments produced Prn2 and PtxA1 (Table 
1). The MAbs were diluted in PBST, added to the wells, 
and incubated for 1 hour at 37°C, followed by 2 wash-
ings. To detect bound MAbs, plates were incubated with 
horseradish peroxidase–conjugated polyclonal rabbit anti-
mouse IgG (DakoCytmation, Glostrup, Denmark), diluted 
in PBST, for 1 hour at 37°C, and followed by 2 washings. 
The optical density at 450 nm was measured with a plate 
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Table 1. Characteristics of strains used for Ptx and Prn production experiments*
Strain Year of isolation Patient age, mo ptxP allele prn allele ptxA allele 
B1834 1999 28 PtxP1 Prn2 PtxA1 
B1836 1999 3 PtxP3 Prn2 PtxA1 
B1865 2000 2 PtxP3 Prn2 PtxA1 
B1868 2000 35 PtxP1 Prn2 PtxA1 
B1878 2000 45 PtxP1 Prn2 PtxA1 
B1917 2000 44 PtxP3 Prn2 PtxA1 
B1920 2000 9 PtxP1 Prn2 PtxA1 
B2030 2001 3 PtxP3 Prn2 PtxA1 
*Ptx, pertussin toxin; Prn, pertactin; ptxP, pertussin toxin promoter; prn, gene for pertactin; ptxA, gene for the A subunit of pertussin toxin. 
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reader (PowerWave HT 340; Biotek, Winooski, VT, USA) 
and the amount of produced Ptx and Prn were calculated 
using the KC4 program (Biotek).The ratio of Ptx and Prn 
production by ptxP1 and ptxP3 strains was calculated as 
follows: Ptx (or Prn) production ptxP3 strains divided by 
Ptx (or Prn) production ptxP1 strains.
Statistical Analyses 
The significance of the increases in illness and death 
were calculated with the Fisher exact test. Ptx and Prn pro-
duction was analyzed on the basis of the following consid-
erations: 1) that there are random variations among experi-
ments that influence Ptx and Prn production; 2) that there 
is a correlation between Ptx and Prn production; and 3) that 
the distribution Ptx and Prn measurements were skewed. 
To take into account these considerations regarding sources 
of random variation, a random intercept model was used 
and a logarithmic transformation was used before further 
analysis. Logarithmically transformed Ptx and Prn values 
were first analyzed with a random intercept model by using 
SAS PROC MIXED (SAS, Cary, NC, USA) and by us-
ing experiment as a random effect. We first tested whether 
there were differences between ptxP1 and ptxP3 strains in 
the production of Ptx and Prn by analyzing the logarithm 
of Ptx production and Prn production, respectively, as a 
dependent variable, and by using experiment as random 
effect and incubation time (in classes) and type (ptxP1 or 
ptxP3) as fixed effects. To determine whether the ratio of 
production in ptxP3 versus ptxP1 strains differ significantly 
for Prn and Ptx, we further fitted a multivariate model with 
both factors (Ptx and Prn) as dependent variables, again us-
ing experiment as random effect, and allowing all variance 
parameters to be factor (Ptx or Prn) specific. In this model 
the interaction between type (ptxP1 or ptxP3) with factor 
(Ptx or Prn) then gives the required P value.
Results
Polymorphism of the Pertussis Toxin Promoter
The synthesis and export of Ptx requires 14 genes, 
which are co-transcribed from ptxP (17). ptxP comprises a 
region of ≈170 bases upstream of the Ptx subunit gene ptxA 
and contains the RNA polymerase binding site and 6 bind-
ing sites for the BvgA dimer (18). BvgA is a global regula-
tor of B. pertussis virulence genes, and cooperative binding 
of BvgA to ptxP is required for efficient transcription of ptx 
(18). We investigated polymorphism in ptxP by sequencing 
a DNA region of ≈380 bases upstream of ptxA by using a 
collection of 1,566 B. pertussis strains from 12 countries 
isolated during 1935–2004. Polymorphism was found to be 
restricted to the DNA region implicated in binding of RNA 
polymerase and BvgA. Eleven ptxP alleles were identified 
(Figure 1).
Geographic and Temporal Differences  
in ptxP Frequencies
Next we investigated geographic and temporal differ-
ences in ptxP frequencies. The following geographic re-
gions were distinguished: the Netherlands, the continents 
of Africa, Asia, Europe (excluding the Netherlands), North 
America, and South America. Two periods, chosen on the 
basis of the appearance of ptxP3 strains in the Netherlands, 
were compared: 1935 through 1990 and 1991 through 2004 
(Table 2). Only strains from the later period were available 
from South America. Two ptxP alleles were found to pre-
dominate worldwide, ptxP1 and ptxP3, and the remaining 9 
alleles were pooled. Strains with ptxP1 predominated in the 
first period and were found in lower frequencies in the sec-
ond period (global frequencies were 88% and 47%, respec-
tively). A reverse trend was observed for the ptxP3 strains 
(global frequencies, 3% and 52%, respectively). In the first 
period, ptxP3 strains were only detected in the Netherlands 
and the United States (frequencies were 3% and 13%, re-
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Figure 1. Alleles of pertussis 
toxin promoter (ptxP) observed 
worldwide. Bases are numbered 
–173 to +27 relative to the start 
of transcription (+1). The region 
to which 6 dimers of BvgA, the 
global regulator of B. pertussis 
virulence genes, bind is shaded. 
The –10 sequence motif and 
initiation codon are underlined. 
The	DNA	 region	 –370	 to	 –174,	
not shown here, was devoid 
of polymorphism. Locations of 
transcriptional signals and BvgA 
bindings sites are based on 
Bartoloni et al. (16).
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spectively). The only region in which ptxP3 strains were not 
detected was Africa, where only ptxP1 strains were found. 
The minor ptxP alleles were observed in higher frequencies 
during 1935–1990 compared with 1991–2004 (global fre-
quencies were 9% and 1%, respectively). The differences 
in ptxP allele frequencies may be due to sampling bias, 
geographic factors, or differences in vaccines, vaccination 
history, and vaccination coverage. Nevertheless, these data 
provide strong evidence that, in most parts of the world, 
ptxP3 strains emerged recently and replaced the resident 
ptxP1 strains. The ptxP3 allele was first detected in a strain 
isolated in the United States in 1984.
To investigate if ptxP1 and ptxP3 alleles were linked 
to other polymorphisms in ptx genes, the gene clusters 
from 2 ptxP1 and 2 ptxP3 strains were sequenced. The ptx 
sequences were identical, except for a single point muta-
tion in ptxC. The single nucleotide polymorphism (SNP) 
in ptxC has been described previously, does not result in 
a change in amino acid sequence, and is therefore most 
likely selectively neutral (19). To study the linkage, ptxC 
was sequenced in 249 ptxP1 and 142 ptxP3 strains. Link-
age between ptxP1-ptxC1 and ptxP3-ptxC2 was 100% and 
98%, respectively. Only 3 strains harbored the combination 
ptxP3-ptxC1.
Association of the ptxP3 Allele with  
the Resurgence of Pertussis in the Netherlands
The availability of a large strain collection allowed us 
to analyze temporal trends in the Netherlands in more de-
tail. From 1989 through 2004, a total of 99% of the strains 
harbored ptxP1 or ptxP3. In this period, ptxP1 was gradu-
ally replaced by ptxP3, which increased in frequency from 
0% in 1989 to 100% in 2004. A close temporal relationship 
was shown between the increase in ptxP3 frequency and 
mandatory pertussis notifications (Figure 2, panel A). In-
creased notifications were found in all age groups, howev-
er, the largest increase was among persons >5 years of age 
(Figure 2, panel B). The shift toward older age categories 
coincided with emergence of ptxP3 strains. There was no 
change in age distribution from 1989 through 1992, which 
preceded the emergence of the ptxP3 allele.
Ptx and Prn Production by ptxP1 and ptxP3 Strains
The effect of polymorphism in ptxP was assessed by 
determining the ratio of Ptx produced by ptxP1 and ptxP3 
strains (Ptx produced by ptxP3 strain / Ptx produced by 
ptxP1 strain) after 48, 54, and 60 h growth on plates. In 
addition, we assessed the production of a second virulence 
factor, Prn, which is also regulated by bvg. No polymor-
phism was observed in the Prn promoter of the 8 strains an-
alyzed. Data from 4 ptxP1 and 4 ptxP3 strains were pooled 
(Figure 3). The Prn ratios were slightly lower than 1, in-
dicating that ptxP3 strains produce slightly less Prn than 
ptxP1 strains (average over all time points 0.94; p = 0.03). 
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Table 2. Worldwide frequencies of ptxP1 and ptxP3 during 1935–1990 and 1991–2004* 
1935–1990 1991–2004
Region† ptxP1 ptxP3 Other‡ N ptxP1 ptxP3 Other‡ N
The	Netherlands	 89 3 8 265 47 53 0 614
Africa 100 0 0 11 100 0 0 7
Asia 100 0 0 12 83 13 3 30
Europe§ 73 0 27 22 46 53 0 577
North	America	 50 13 38 8 20 80 0 10
South America – – – 0 10 80 10 10
Total 88 3 9 318 47 52 1 1,248
*ptxP, pertussis toxin promoter. Allele frequencies are given in percentages. 
†The	following	countries	represented	the	continents:	Africa:	Senegal;	Asia:	Japan	and	Australia;	Europe:	Denmark,	Finland,	France, Germany, Italy, 
Sweden;	North	America:	USA;	South	America:	Argentina.	
‡Nine ptxP	alleles	were	found	in	low	frequencies:	ptxP2, ptxP4, ptxP5, ptxP6, ptxP7, ptxP8, ptxP9, ptxP10, and ptxP11.
§Dutch strains were excluded. 
Figure 2. Relationship between the emergence of pertussis toxin 
promoter 3 (ptxP3) strains and the epidemiology of pertussis in the 
Netherlands,	1989–2004.	A)	Temporal	trends	in	the	frequencies	of	
ptxP3	 strains	 and	 notifications.	 In	 this	 period	 99%	of	 the	 strains	
harbored either ptxP1 or ptxP3.	B)	Shift	in	age-specific	distribution	
of	notifications.
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In contrast, the Ptx ratio was significantly larger than 1 (av-
erage over all time points 1.62; p<0.0001), indicating that 
ptxP3 strains produce more Ptx than ptxP1 strains under 
the growth conditions tested. The Ptx and Prn ratios were 
significantly different (p<0.0001).
Evidence for Increased Virulence of  
ptxP3 Strains in Humans
Ptx is assumed to contribute to the severity of infec-
tion. Therefore, we investigated whether ptxP3 strains were 
more virulent in humans than ptxP1 strains by comparing 
the incidence of hospitalizations, deaths, and lethality (ratio 
of deaths to hospitalizations) in the Netherlands during 2 
periods, 1981 through 1992 and 1993 through 2004, with 
low (1.6%) and high (54.5%) ptxP3 frequencies, respec-
tively (Table 3). All 3 parameters showed a statistically sig-
nificant increase (1.41, 10.21, and 7.23 times respectively; 
p values <0.0001, 0.0058, and 0.03, respectively), suggest-
ing that ptxP3 strains are more virulent in humans.
Discussion
The persistence of pertussis in the face of intense vac-
cination is unexpected because B. pertussis is extremely 
homogeneous (19–21), implying a limited ability to adapt. 
However, the Ptx promoter showed a relatively high degree 
of polymorphism, suggesting that fine tuning of Ptx pro-
duction has adaptive value. Globally, 11 ptxP alleles were 
found in 1,566 strains, 8 of which occurred in the B. pertus-
sis population in the Netherlands. Polymorphism was re-
stricted to a region required for transcription of ptx. Silent 
ptx genes are found in the closely related species B. parap-
ertussis and B. bronchiseptica (17). The silencing of ptx 
genes indicates that production of Ptx involves benefits and 
costs. Thus, production of Ptx is beneficial for the pathogen 
by suppressing host defenses but also involves metabolic 
costs and increases the number of immunologic targets. Ptx 
is a major antigen of B. pertussis, and Ptx antibodies are 
used in diagnosing pertussis cases.
Globally, ptxP1 and ptxP3 were the most prevalent 
ptxP alleles. In the Netherlands, during 1989–2004, ptxP1 
was completely replaced by ptxP3. The replacement of 
ptxP1 strains by ptxP3 strains in recent times is a global 
phenomenon because it has been observed in 11 countries 
representing 4 continents; Asia, Europe, and North and 
South America. Notably, ptxP3 strains were not observed 
in Africa. A broad current distribution of ptxP3 strains was 
also suggested by a recent study in which strains from 8 
European countries were compared by pulsed-field gel 
electrophoresis (PFGE). One PFGE profile, BpSR11, pre-
dominated in 5 of the 8 European countries (22). We have 
found that in the Dutch population all BpSR11 strains carry 
the ptxP3 allele (N = 18).
In the Netherlands, emergence of ptxP3 strains was 
associated with increased notifications and a shift in dis-
ease prevalence toward older age categories. Changes in 
diagnostic procedures may have contributed to the latter 
2 phenomena (3). However, hospitalizations, which are 
less sensitive to surveillance artifacts, also increased con-
currently with the emergence of ptxP3 strains (online Ap-
pendix Figure, available from http://www.cdc.gov/EID/
content/15/8/1206-appF.htm). Furthermore, an extensive 
analysis of surveillance data confirmed a true increase in 
the pertussis incidence after 1995 in the Netherlands (3). 
The expansion of ptxP3 strains was also associated with 
the resurgence of pertussis in Finland, where a large nation-
wide epidemic was observed in 2003 (23).
The SNP distinguishing the ptxP1 and ptxP3 alleles is 
located in a region involved in binding of BvgA, the global 
regulator of virulence gene expression in B. pertussis. We 
hypothesize that the ptxP3 allele confers increased binding 
of BvgA compared to ptxP1, resulting in increased toxin pro-
duction. When compared with ptxP1 strains, ptxP3 strains 
produced 1.62 times more Ptx. In contrast, the production of 
another bvg-regulated virulence factor, Prn, was slightly sup-
pressed in ptxP3 strains compared with ptxP1 strains (factor 
0.94), indicating that increased Ptx production cannot be ex-
plained by a global up-regulation of virulence genes.
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Figure 3. Production of pertussis toxin (Ptx) and pertactin (Prn) by 
pertussis toxin promoter 1 (ptxP1) and ptxP3 strains. Strains were 
incubated for the 48, 54, and 60 h, after which the amount of Ptx and 
Prn was determined by ELISA. The production ratio was calculated 
as	 follows:	 ptxP3	 strain	 values/ptxP1 strain values; 8 strains, 4 
ptxP1 strains and 4 ptxP3 strains, were used. The experiment was 
performed	3	 times.	Error	bars	 indicate	95%	confidence	 intervals.	
The	Ptx	and	Prn	ratios	were	significantly	different	from	1	(p<0.0001	
and 0.03, respectively).
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The expansion of ptxP3 strains is remarkable and sug-
gests that ptxP3 increases strain fitness or is linked to other 
genetic loci that do so. Although we cannot exclude that 
other loci are involved in the expansion of ptxP3 strains, 
several arguments underline the role of ptxP3. First, the 
high degree of polymorphism in the ptxP promoter indi-
cates positive selection. Second, the increased Ptx produc-
tion observed by ptxP3 strains provides a rationale for its 
emergence. It has been well established that Ptx plays a cen-
tral role in immune suppression. Ptx enhances colonization 
of naive and immune mice by targeting macrophages and 
neutrophils (24,25). Ptx also suppresses antibody responses 
(26). The ptxP3 allele was found to be associated with 2 
ptxC alleles, ptxC1 and ptxC2, which are distinguished by 
a silent SNP. This finding suggests that the ptxP3 allele 
is found in different genetic backgrounds, which may be 
explained by homoplasy or horizontal gene transfer. Both 
possibilities suggest that ptxP3 confers increased fitness. 
In most strains (98%), ptxP3 was linked to ptxC2. Further-
more, genomic profiling of Dutch B. pertussis strains indi-
cates that ptxP3 strains are closely related, and are charac-
terized by a chromosomal deletion (27). Thus, it is likely 
that, in the Netherlands, ptxP3 strains arose mainly by clon-
al expansion. We are analyzing a geographically more di-
verse strain collection to investigate this issue further.
Ptx has been suggested to increase severity of B. per-
tussis infections because the closely related B. parapertus-
sis, which does not produce Ptx, generally causes less se-
vere infections (28). Furthermore, Ptx causes leukocytosis 
in humans by inhibiting egression of leukocytes from the 
vasculature, and high levels of leukocytosis are associated 
with an increased mortality rate in infants due to pulmonary 
hypertension (29). Thus, the invasion of ptxP3 strains may 
result in increased illness and death. Consistent with this 
assumption, we found that the emergence of ptxP3 strains 
in the Netherlands was associated with increased incidence 
of hospitalizations and deaths and increased lethality. A re-
cent Swedish study also suggested that B. pertussis strains 
differ in virulence. Infection with strains with PFGE profile 
BpSR11 was associated with a longer duration of hospital 
stay (30). As noted above, BpSR11 strains carry the ptxP3 
allele. An association between Fim2 and increased disease 
severity was found in a study in the UK (31). In contrast, 
the Swedish study found no association between Fim type 
and virulence (30). Nevertheless, it is conceivable that other 
polymorphic loci in B. pertussis may also affect virulence.
An important issue is whether vaccination has selected 
for the ptxP3 strains. Several lines of evidence support this 
contention. First, ptxP3 strains were not found in the pre-
vaccination era. Furthermore, although ptxP3 strains were 
found in high frequencies in vaccinated populations in the 
1990s, they were not detected in Senegal, where vaccina-
tion was introduced in 1987 (32). Several studies have pro-
vided evidence that increased host immunity may select for 
higher virulence. Vaccination against 2 avian viruses, the 
Marek disease virus, and the infectious bursal disease vi-
rus, were associated with the emergence of more virulent 
strains (33). An important role of host immunity in select-
ing for virulence is also suggested by the co-evolution of 
the myxomatosis virus and rabbits (34). Furthermore, im-
mune pressure was shown to select for more virulent Plas-
modium chabaudi parasites in mice (35). Based on math-
ematical modeling, vaccines designed to reduce pathogen 
growth rate and/or toxicity may result in the evolution of 
pathogens with higher levels of virulence (36).
We propose that the crucial event, which shifted the 
competitive balance between ptxP1 and ptxP3 strains, was 
the removal by vaccination of immunologically naive in-
fants as the major source for transmission, selecting for 
strains, which are more efficiently transmitted by primed 
hosts. Recent studies and historical data indicate an impor-
tant role of naïve infants in transmission in unvaccinated 
populations. In a previously unvaccinated population, in-
fant vaccination resulted in a reduction in pertussis in the 
vaccinated and unvaccinated parts of the population (37). 
Furthermore, in unvaccinated populations, 60%–80% of 
the pertussis cases were found in children 0–5 years of 
age, most of whom were probably immunologically naive 
(32,38). In most countries infants receive their first vacci-
nation at the age of 2 or 3 months, essentially eliminating 
transmission by immunologically naive hosts. In primed 
hosts, increased Ptx production may delay an effective 
immune response (24–26) enhancing transmission, and 
hence, pathogen fitness. Increased Ptx production may also 
be beneficial for the pathogen because the host requires 
higher levels of antibodies against Ptx for toxin neutraliza-
tion. The antigenic divergence observed between vaccine 
strains and circulating strains (8,9) may act synergistically 
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Table 3. Increases in illness and death caused by pertussis in 2 periods with low and high frequencies of ptxP3 strains in the 
Netherlands*
Parameter ptxP3	frequency,	%	 Hospitalizations/100,000	 Deaths/100,000 Lethality†
1981–1992 1.6 1.38 0.00057 0.00041
1993–2004 54.5 1.95 0.00582 0.00299
Increase 33.1 1.41 (1.34–1.49) 10.21 (1.31–79.11) 7.23 (0.93–56.07)
p value <0.0001 0.0058 0.03
*ptxP,	pertussis	toxin	promoter.	Numbers	in	parentheses	are	95%	confidence	intervals.	
†Lethality	=	no.	of	deaths	/	no.	of	hospitalizations.	
RESEARCH
with the ptxP3 polymorphism by enhancing transmission 
by hosts primed by vaccination. Pertussis among recently 
vaccinated children is rare, indicating that pathogen adapta-
tion does not play a role unless immunity has waned. Thus, 
we propose that waning immunity and pathogen adaptation 
have contributed to the resurgence of pertussis, although 
other factors such as increased awareness and improved di-
agnostics have also played a role.
The effect of pathogen adaptation on disease impact 
may depend on factors such as vaccine coverage and the 
quality of the vaccine used, which may differ between 
countries. A relatively weak vaccine used in the Nether-
lands may have exacerbated the effect of the emergence of 
ptxP3 strains on disease impact (3). Our results underline 
the important role of Ptx in the transmission of B. pertussis 
and suggest that an effective way to control pertussis is the 
improvement of current vaccines to induce Ptx-neutraliz-
ing antibodies which persist longer. An important question 
is whether other childhood vaccines also select for patho-
gens that are more efficiently transmitted by primed hosts, 
resulting in increased virulence.
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